Category 5 cannabis products account for nearly half of all unapproved medicinal cannabis applications to the TGA. But they lack evidence for their safety or efficacy at THC concentrations above 22%, a rapid review published in Drug and Alcohol Review has found.

The research team from Monash Addiction Research Centre screened 9969 studies from the past decade for eligibility, but only 15 were included in the review, two of which were from Australia.

Long-term efficacy implications were especially limited, with five of the 15 studies using only a single dose.

Adverse events – predominantly dizziness, cough, nausea, drug highs and anxiety – were mild to moderate and tied to the total THC dose rather than its concentration.

As it stands, only two medicinal cannabis products have ever undergone pre-market TGA evaluation.

In a separate analysis published in the Royal Australian and New Zealand College of Psychiatrists (RANZCP’s) journal , more than half of the adverse events reported to the TGA from mid-2022 to mid-2025 were linked to category 5 products.